Progenics Stock Drops After Study Reveals Two Deaths in Trial

Jan 30, 2014


Progenics Pharmaceuticals Inc., Tarrytown, N.Y., stocks fell nearly 20 percent after a study summary showed two patients died of sepsis in a trial of the company’s experimental prostate cancer treatment. The study abstract appears to show that even at a lower dose of the drug, PSMA-ADC, patients could experience life-threatening levels of toxicity, said Brian Klein, an analyst at New York-based Stifel Nicolaus & Co. Read the full story